SCHEMBL1269558

SCHEMBL1269558

CCCCc1nc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Sc1ccc(S(=O)(=O)N2CCCCC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 2/20 0.42
▸ PTGDR Q13258 1/20 0.42
▸ ALDH1A1 P00352 5/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MAPK1 P28482 2/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ TSHR P16473 4/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ RECQL P46063 1/20 0.38
▸ MAPT P10636 4/20 0.38
▸ TP53 P04637 2/20 0.38
▸ POLB P06746 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HTT P42858 3/20 0.36
▸ GAA P10253 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1269679 0.92 PTGDR2 (0.41) PTGDR2PTGDRALDH1A1MEN1LMNA
SCHEMBL1268625 0.90 ALDH1A1 (0.39) PTGDR2PTGDRALDH1A1MEN1LMNA
SCHEMBL1269368 0.89 PTGDR (0.39) PTGDR2PTGDRALDH1A1MEN1LMNA
SCHEMBL1269875 0.86 PTGDR (0.39) PTGDR2PTGDRALDH1A1MEN1LMNA
SCHEMBL1269486 0.86 ALDH1A1 (0.44) PTGDR2ALDH1A1MEN1LMNAKMT2A
SCHEMBL1270163 0.85 ALDH1A1 (0.41) PTGDR2PTGDRALDH1A1MEN1LMNA
SCHEMBL1269799 0.85 PTGDR2 (0.40) PTGDR2PTGDRALDH1A1MEN1LMNA
SCHEMBL1269276 0.85 MAPT (0.41) PTGDR2PTGDRALDH1A1MEN1LMNA
SCHEMBL12900221 0.84 ALDH1A1 (0.41) PTGDR2PTGDRALDH1A1MEN1LMNA
SCHEMBL13452398 0.84 L3MBTL1 (0.38) PTGDR2PTGDRALDH1A1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
EP-1786782-A2 BISARYL-SULFONAMIDES Amgen Inc. (US) 2007-05-23 — — EP disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 — — US disclosed
WO-2006020830-A2 BISARYL-SULFONAMIDES AMGEN INC. (US) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG PTGDR2 649/4885PTGDR 709/4885ALDH1A1 2237/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG PTGDR2 649/4885PTGDR 709/4885ALDH1A1 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback